NSE: NEULANDLAB | BSE: 524558

Expensive Performer

Download real time

12060.00 -282.00 (-2.28%)

33.37% Fall from 52W High

16,472 NSE+BSE Volume

NSE 06 May, 2025 3:31 PM (IST)

15,472.9

Market Cap

High in industry

0.9

Beta 1Year

Low volatility

US FDA Observation

Neuland Labs gets Form 483 with one observation from the US FDA for its Sangareddy facility See details

Neuland Laboratories Ltd. share price target and research reports

Name: Latest research reports of Neuland Laboratories Ltd. authored by BP Wealth and published by - Trendlyne research reports.
Item: Neuland Laboratories Ltd.
Rating: 5
Author: BP Wealth

Latest analyst research reports with target prices and PDF download for NEULANDLAB, BSE:524558 Neuland Laboratories Ltd.

Search Inside the pdf :

Neuland Laboratories Ltd.

25 Jun 2024

12060.00

-2.28%

Improved products mix to drive growth

Not Rated: Neuland Laboratories Ltd.

KRChoksey

Neuland Labs (NEULANDLAB) is a small cap API and CDMO player, since 1984, promoted by Dr. Davuluri Rama Mohan Rao (Executive Chairman), who has a Postgraduate Diploma in Synthetic Drugs and Fine Chemicals Technology from IIT, Kharagpur and a PhD in organic chemistry from the University of Notre Dame, USA. It is being steered by his sons, Mr. Davuluri Sucheth Rao (Vice Chairman and CEO) and Mr. Davuluri Saharsh Rao (Vice Chairman and MD) who have been with the company since 2002 and 2007, respectively.

Neuland Laboratories Ltd. has lost -23.95% in the last 6 Months

Neuland Laboratories Ltd.

11 May 2022

12060.00

-2.28%

BP Equities Neuland Lab Ltd Q4FY22 Result Update

Buy: Neuland Laboratories Ltd.

Target

BP Wealth

Neuland Laboratories Ltd. has gained 59.57% in the last 1 Year

Neuland Laboratories Ltd.

02 Feb 2022

12060.00

-2.28%

BP Equities Neuland Lab Ltd Q3FY22 Result Update

Buy: Neuland Laboratories Ltd.

Recommendation Target

BP Wealth

Neuland lab (NLL) reported revenue of INR 2,365mn (-3.6% YoY, -8.3% QoQ), which was above our estimate of INR 1799mn mainly due to lower than expected decline in the Speciality API and healthy sequential improvement in CMS business. On a segmental side, Prime API business (47% of revenue in FY21) de-grew by 19.3% YoY, mainly impacted by customers' issues on the market-share and inventory front for two of their key products ( Levetiracetam and Mirtazapine). Specialty API business had a decent quarter (+7.1 YoY) with a key contribution from Ezetimibe. Despite the absence of revenue from the Key product, CMS business reported the highest ever quarterly revenues in Q3 with a growth of 4.2% YoY basis. On a sequential basis, CMS revenue improved by 36%, on account of 173% QoQ growth in commercial revenue. Management expects at least two molecules to be...

Neuland Laboratories Ltd. has lost -23.95% in the last 6 Months

Neuland Laboratories Ltd.

01 Nov 2021

12060.00

-2.28%

BP Equities Neuland Lab Ltd Q2FY22 Result Update

Hold: Neuland Laboratories Ltd.

Recommendation Target

BP Wealth

...

Neuland Laboratories Ltd. is trading above its 50 day SMA of 11730.4

Neuland Laboratories Ltd.

05 Aug 2021, 12:00AM

12060.00

-2.28%

BP Equities Neuland Lab Ltd Q1FY22 Result Update

Sell: Neuland Laboratories Ltd.

Recommendation Target

BP Wealth

commercial revenue (-24% YoY). As per our understanding, the company has not made any shipment Stock of its one key product (24% of CMS revenue ) in this calendar year. Reported EBITDA margin contracted by 369bps to 12.8% level (vs our estimate of 15.3%) impacted largely due to Increase in raw material prices and upfront costs for certain projects. However, management is confident of improving margin profile from the current level on the back of a strong order book in CMS business, better traction in GDS business, and cost optimization measures. NLL reported a PAT of INR 87mn...

Number of MF schemes increased from 16 to 23 in Mar 2025 qtr.

Neuland Laboratories Ltd.

13 May 2021

12060.00

-2.28%

BP Equities Neuland Lab Ltd Q4FY21 Result Update

Hold: Neuland Laboratories Ltd.

Target

BP Wealth

growth in profitability, healthy balance sheet with improving return ratios, we continue to remain Face Value (INR) optimistic about the mid to long-term growth prospects of the company. The stock has experienced a Average volume significant re-rating in the recent past as the company has been consistently delivering strong growth 3 months along with margin expansion. We foresee a 16.7% revenue CAGR, 277bps margin increase over 6 months FY21-23E. The balance of portfolio among high value and high volume products will help it clock a 1 year faster growth in earnings. Considering better growth visibility, we raised our earnings estimate for...

Neuland Laboratories Ltd. is trading above its 50 day SMA of 11730.4

Neuland Laboratories Ltd.

03 Feb 2021

12060.00

-2.28%

BP Equities Neuland Lab Ltd Q3FY21 Result Update

Hold: Neuland Laboratories Ltd.

Target

BP Wealth

Neuland lab (NLL) has posted revenue of INR 2,454mn with a 20.4% YoY increase, which was 14% above our estimate of INR 2,150mn. The revenue growth was mainly driven by strong traction in the CMS (78.6% YoY growth) segment, led by 33 molecules (Development + Commercialize) along with the Speciality API segment, which grew by 20.5% in Q3FY21. EBITDA margin expanded by 510bps to 19% level, which was 76bps higher than our estimate driven by improved product mix. Management is confident to improve margin profile from the current level on the back of strong order book in CMS business, better traction in GDS business, and cost optimization measures. NLL reported a PAT of INR 267mn (up 141% YoY) compared to our PAT estimate of INR 202mn led by operationally...

Neuland Laboratories Ltd. has lost -23.95% in the last 6 Months

Neuland Laboratories Ltd.

04 Nov 2020

12060.00

-2.28%

BP Equities Neuland Lab Ltd Q2FY21 Result Update

Hold: Neuland Laboratories Ltd.

Recommendation Target

BP Wealth

Neuland lab (NLL) has posted revenue of INR2,414mn with a 29.6% YoY increase, which was 12% below our estimate of INR 2,160mn. The revenue growth was mainly driven by strong traction in the CMS (54.6% YoY growth) segment, led by 33 molecules (Development + Commercialize) along with...

Number of MF schemes increased from 16 to 23 in Mar 2025 qtr.

Neuland Laboratories Ltd.

05 Aug 2020, 12:00AM

12060.00

-2.28%

BP Equities Neuland Lab Ltd Q1FY21 Result Update

Buy: Neuland Laboratories Ltd.

Recommendation Target

BP Wealth

low our estimate of INR 2,149mn. The revenue growth was mainly driven by the CMS (25.4% YoY growth) segment, led by 32 molecules (Development + Commercialize) with speciality API segment, which grew by 33.2% in Q1FY21. EBITDA margin expanded by 622bps to 16.5% level, which was 219bps higher than our estimate driven by 580bps improvement in gross margin led by improved product mix. Management is confident to improve margin profile from current level on the back of strong order book in CMS business, better traction in GDS business and cost optimization measures....

Neuland Laboratories Ltd. has gained 59.57% in the last 1 Year

Neuland Laboratories Ltd.

24 May 2020

12060.00

-2.28%

BP Equities Neuland Lab Ltd Q4FY20 Result Update

Sell: Neuland Laboratories Ltd.

Recommendation Target

BP Wealth

below our estimate of INR 2,032mn. The revenue growth was mainly driven by the CMS (62% YoY growth) segment, led by 25 molecules with speciality API segment, which grew by 18.9% in Q4FY20. EBITDA margin expanded by 498bps to 15.6% level, which was 274bps higher than our estimate due...

Number of MF schemes increased from 16 to 23 in Mar 2025 qtr.

Is Neuland Laboratories Ltd. worth buying?

172 Votes:

Buy 76.74%

Sell 14.53%

Hold 8.72%

RESEARCH REPORTS

Not Rated SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf